Gilead's HIV-1 capsid inhibitor, lenacapavir, reduced new HIV infections by 96% in a trial, outperforming Truvada.
Gilead Sciences has reported that its HIV-1 capsid inhibitor, lenacapavir, reduced new HIV infections by 96% in a late-stage trial, outperforming the daily pill Truvada. The independent committee recommended halting the blinded study to offer lenacapavir to all participants. Gilead plans to submit for FDA approval by late 2024, aiming for a market launch in 2025. However, the high potential cost of lenacapavir poses challenges for widespread access.
September 12, 2024
17 Articles